DentalMonitoring Expands into Japan

DentalMonitoring, the leading global provider of smart dentistry solutions, is setting foot in Japan to serve the Asian market with its AI-powered remote monitoring solution and latest clinical data analysis platform DM Insights.

Having been granted market authorization, the company headquartered in Paris, France, is now bringing its suite of intelligent solutions onto the Japanese market. From lead engagement and conversion to remote monitoring of all treatment modalities, DentalMonitoring has helped transform over 7,000 practices worldwide and over 1 million patients have already been using its ScanBoxᵖʳᵒ and 4.9 rated app, helping optimize their treatment experience. ScanBoxᵖʳᵒ will be available from Dental Monitoring Japan in October 2022.

“We are very excited to be engaging with the Japanese market, one of the most dynamic in terms of advanced technologies and Artificial Intelligence,” says Philippe Salah, DentalMonitoring’s Chief Executive Officer.

By leveraging the power of data, DentalMonitoring helps improve quality of care, enables practices optimization and growth and enhances patient experience. To support the market, DentalMonitoring has set up a new direct sales team to help on-board and grow customers. The team will be led by Hiroyuki Nishiya, General Manager, who was formerly 3Shape Japan. Press conference will be held on 5th Wednesday October at “Dental Monitoring Room”, Rihga Royal Osaka at 13:00 JST.

DentalMonitoring represents the most significant innovation leap that the industry has known over the last decade. The company’s strategy has always been based on building close relationships with orthodontists, understanding their needs and constantly improving its solutions. Today, I’m delighted to help Japanese practices jump into this new era of smart dentistry,” says Hiroyuki Nishiya, General Manager DM Japan.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”